CPR is short for cardiopulmonary resuscitation. It’s a life saving medical procedure which is given to someone who is in cardiac arrest. It helps to pump blood around the person's body when their heart can’t. To carry out CPR a person presses up and down on the casualty’s chest (chest compressions<span>) and gives them a series of rescue breaths to help save their life when they are in cardiac arrest. At 6 min, CPR was started with an automated chest compressor at a rate<span> of 200-240/min.
more information, https://www.ncbi.nlm.nih.gov/pubmed/19520479
</span></span>
Answer:
b) dumping used oil into street drains
Explanation:
Plant pollen can provide information of what type of plants grew during that era and area. In turn, it can also determine how the Earth''s climate has changed over time. Identifying the species of the plants through the pollen will help because when scientists compare them to the plants today and the climates they thrive in, they will be able to tell what type of climate that certain plant existed in.
The answer is True.
Mosunetuzumab is a T-cell reliant bispecific antibody that binds to CD3 and CD20 to trigger T-cell mediated B-cell death.
However, cytokine release syndrome, which has the potential to limit dose and efficacy, can result from powerful immune stimulation with T-cell focused treatments.
We created a novel mechanistic model of immune and antitumor responses to the T-cell bispecifics (mosunetuzumab and blinatumomab), taking into account the dynamics of B- and T-lymphocytes in circulation, lymphoid tissues, and tumors, in order to better understand the mechanisms underlying safety and efficacy as well as to explore safety mitigation strategies.
Using mosunetuzumab nonclinical and blinatumomab clinical data, the model was created and validated. The initial step-fractionated dose was projected to minimize systemic T-cell activation and cytokine release without impairing tumour response.
Simulations described the mechanisms underlying the observed cell and cytokine (IL6) dynamics. The Phase I clinical study for mosunetuzumab was changed to a step-fractionated treatment schedule as a result of these findings, allowing for the safer administration of greater dosages.
Learn more about cytokine brainly.com/question/14161482
#SPJ4
